

# CITATION REPORT

List of articles citing

## Tofacitinib for refractory uveitis and scleritis

DOI: 10.1016/j.ajoc.2018.12.001

American Journal of Ophthalmology Case Reports,  
2019, 13, 53-55.

**Source:** <https://exaly.com/paper-pdf/74789747/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
62	Maneuvering Clinical Pathways for Ulcerative Colitis. <i>Current Gastroenterology Reports</i> , <b>2019</b> , 21, 52	5	2
61	Emerging drugs for the treatment of noninfectious uveitis. <i>Expert Opinion on Emerging Drugs</i> , <b>2019</b> , 24, 173-190	3.7	5
60	JAK inhibitors for the treatment of autoimmune and inflammatory diseases. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 102390	13.6	118
59	Multiple drugs. <i>Reactions Weekly</i> , <b>2019</b> , 1736, 144-144	0	
58	Tofacitinib for the treatment of rheumatoid arthritis: an update. <i>Expert Review of Clinical Immunology</i> , <b>2019</b> , 15, 577-588	5.1	12
57	Janus Kinase inhibitors in the New Treatment Paradigms of Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , <b>2020</b> , 14, S761-S766	1.5	6
56	JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. <i>Clinical Rheumatology</i> , <b>2020</b> , 39, 847-851	3.9	51
55	Biotherapies in Uveitis. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	10
54	Ocular Sarcoidosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2020</b> , 41, 673-688	3.9	7
53	The current status of biological treatment for uveitis. <i>Expert Review of Clinical Immunology</i> , <b>2020</b> , 16, 787-811	5.1	4
52	Uveitis in spondyloarthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2020</b> , 12, 1759720X20951733	3.3	14
51	Paediatric autoimmune and autoinflammatory conditions associated with uveitis. <i>Therapeutic Advances in Ophthalmology</i> , <b>2020</b> , 12, 2515841420966451	2	4
50	Behçet's disease uveitis: is there a need for new emerging drugs?. <i>Expert Opinion on Emerging Drugs</i> , <b>2020</b> , 25, 531-547	3.7	2
49	Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 6067-6074	11.5	10
48	Emerging treatment options for extraintestinal manifestations in IBD. <i>Gut</i> , <b>2021</b> , 70, 796-802	19.2	9
47	Ocular Manifestations of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, 1832-1838	4.5	3
46	The Effect of an Intravitreal Dexamethasone Implant for Refractory Posterior Scleritis. <i>Journal of Korean Ophthalmological Society</i> , <b>2021</b> , 62, 322-328	0.2	0

45	Protective effect of filgotinib in rat endotoxin-induced uveitis model. <i>International Ophthalmology</i> , <b>2021</b> , 41, 2905-2912	2.2	1
44	Old and New Challenges in Uveitis Associated with Behçet's Disease. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
43	JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials. <i>Expert Review of Clinical Immunology</i> , <b>2021</b> , 17, 701-715	5.1	6
42	Rheumatoid Arthritis Associated Episcleritis and Scleritis: An Update on Treatment Perspectives. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
41	Behçet disease: From pathogenesis to novel therapeutic options. <i>Pharmacological Research</i> , <b>2021</b> , 167, 105593	10.2	4
40	Pediatric uveitis: A comprehensive review. <i>Survey of Ophthalmology</i> , <b>2021</b> ,	6.1	3
39	Tofacitinib for refractory ocular mucous membrane pemphigoid. <i>American Journal of Ophthalmology Case Reports</i> , <b>2021</b> , 22, 101104	1.3	0
38	IL-17A Damages the Blood-Retinal Barrier through Activating the Janus Kinase 1 Pathway. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	6
37	Perspectives for immunotherapy in noninfectious immune mediated uveitis. <i>Expert Review of Clinical Immunology</i> , <b>2021</b> , 17, 977-989	5.1	0
36	Novel strategies for the diagnosis and treatment of scleritis. <i>Expert Review of Ophthalmology</i> , 1-18	1.5	
35	Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review. <i>Ophthalmology and Therapy</i> , <b>2021</b> , 10, 777-813	5	1
34	Peripheral ulcerative keratitis. <i>Survey of Ophthalmology</i> , <b>2021</b> , 66, 977-998	6.1	4
33	Response to: 'Correspondence on 'A pilot study of tofacitinib for refractory Behçet's syndrome'' by Zou. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	1
32	Current Approach for the Diagnosis and Management of Noninfective Scleritis. <i>Asia-Pacific Journal of Ophthalmology</i> , <b>2020</b> , 10, 212-223	3.5	6
31	Tofacitinib in recalcitrant scleritis: First case report from India. <i>Indian Journal of Ophthalmology</i> , <b>2020</b> , 68, 1988-1990	1.6	6
30	Therapie mit Januskinasehemmern bei Autoimmunerkrankungen und Interferonopathien. <i>Kinder-Und Jugendmedizin</i> , <b>2021</b> , 21, 329-338	0	
29	Scleritis. <b>2020</b> , 252-258		
28	Tofacitinib in Vogt-Koyanagi-Harada disease. <i>Indian Journal of Ophthalmology</i> , <b>2020</b> , 68, 1938-1939	1.6	3

27	Approaches to Medical Therapy. <b>2020</b> , 73-102		
26	Commentary: Janus kinase inhibitors and their use in autoimmune ocular inflammatory disorders. <i>Indian Journal of Ophthalmology</i> , <b>2020</b> , 68, 1939-1940	1.6	
25	Tofacitinib Ameliorates Retinal Vascular Leakage in a Murine Model of Diabetic Retinopathy with Type 2 Diabetes. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	0
24	HLA-B27 assoziierte anteriore Uveitis: Herausforderung fñeine interdisziplinäre Zusammenarbeit. <i>Aktuelle Rheumatologie</i> , <b>2021</b> , 46, 524-531	0.1	
23	Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid Arthritis and Uveitis: A Case Report.. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 764067	4.9	1
22	Choosing the right biologic for complications of inflammatory bowel disease.. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2022</b> ,	4.2	1
21	Current Knowledge of Biologics in Treatment of Noninfectious Uveitis.. <i>Journal of Ocular Pharmacology and Therapeutics</i> , <b>2022</b> ,	2.6	1
20	Biologics in Uveitis. <b>2022</b> , 225-235		
19	Immunopathological Analysis of a Mouse Model of Arthritis-Associated Scleritis and Implications for Molecular Targeted Therapy for Severe Scleritis.. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 23,	6.3	1
18	Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review.. <i>Journal of Immunology Research</i> , <b>2021</b> , 2021, 2324400	4.5	1
17	Janus Kinase Inhibitors: Next-Generation Treatment for Uveitis.. <i>Klinische Monatsblätter Fur Augenheilkunde</i> , <b>2022</b> , 239,	0.8	0
16	Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2022</b> , 14, 1759720X221093211	3.8	1
15	Ocular involvement in rheumatoid arthritis ¶literature review. <i>Medic Ro</i> , <b>2022</b> , 2, 7	0	
14	Intermediate Uveitis in an HLA-B27-Positive Patient Treated with Upadacitinib.. <i>Klinische Monatsblätter Fur Augenheilkunde</i> , <b>2022</b> , 239, 572-574	0.8	0
13	Management Strategies of Juvenile Idiopathic Arthritis-Associated Chronic Anterior Uveitis: Current Perspectives. <i>Clinical Ophthalmology</i> , Volume 16, 1665-1673	2.5	1
12	Genetics in Behcet¶ Disease: An Update Review. 2,		
11	Progress in the pharmacotherapy of uveitis: the art of personalized care. 1-11		
10	JAK-STAT signaling pathway in non-infectious uveitis. <b>2022</b> , 204, 115236		0

- 9 Tofacitinib in Scleritis: A Case Series. 1-7 ○
- 8 Insights gained from single-cell analysis of immune cells in tofacitinib treatment of Vogt-Koyanagi-Harada disease. ○
- 7 Baricitinib in severe and refractory peripheral ulcerative keratitis: a case report and literature review. **2022**, 14, 1759720X2211371 ○
- 6 Beneficial Effect of Upadacitinib in a Refractory Course of Scleritis: A Case Report. 1-3 ○
- 5 Novel therapies in axial spondyloarthritis. **2022**, 101811 ○
- 4 New possibilities in therapy of ocular inflammation in rheumatic diseases. **2022**, 138, 108 ○
- 3 Treatment Options in Pediatric Behçet Disease. ○
- 2 JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases. 10, ○
- 1 Can we change the natural course of inflammatory bowel disease?. **2023**, 16, 175628482311631 ○